BIOMAT Database Logo BIOMAT Database Logo

Florbetapir positron emission tomography and cerebrospinal fluid biomarkers. 2015

Ann Hake, and Paula T Trzepacz, and Shufang Wang, and Peng Yu, and Michael Case, and Helen Hochstetler, and Michael M Witte, and Elisabeth K Degenhardt, and Robert A Dean, and
Eli Lilly and Company, Indianapolis, IN, USA; Department of Neurology Indiana University School of Medicine, Indianapolis, IN, USA. Electronic address: hakean@lilly.com.

BACKGROUND We evaluated the relationship between florbetapir-F18 positron emission tomography (FBP PET) and cerebrospinal fluid (CSF) biomarkers. METHODS Alzheimer's Disease Neuroimaging Initiative-Grand Opportunity and Alzheimer's Disease Neuroimaging Initiative 2 (GO/2) healthy control (HC), mild cognitive impairment (MCI), and Alzheimer's disease (AD) dementia subjects with clinical measures and CSF collected ±90 days of FBP PET data were analyzed using correlation and logistic regression. RESULTS In HC and MCI subjects, FBP PET anterior and posterior cingulate and composite standard uptake value ratios correlated with CSF amyloid beta (Aβ1-42) and tau/Aβ1-42 ratios. Using logistic regression, Aβ1-42, total tau (t-tau), phosphorylated tau181P (p-tau), and FBP PET composite each differentiated HC versus AD. Aβ1-42 and t-tau distinguished MCI versus AD, without additional contribution by FBP PET. Total tau and p-tau added discriminative power to FBP PET when classifying HC versus AD. CONCLUSIONS Based on cross-sectional diagnostic groups, both amyloid and tau measures distinguish healthy from demented subjects. Longitudinal analyses are needed.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D010446 Peptide Fragments Partial proteins formed by partial hydrolysis of complete proteins or generated through PROTEIN ENGINEERING techniques. Peptide Fragment,Fragment, Peptide,Fragments, Peptide
D011569 Psychiatric Status Rating Scales Standardized procedures utilizing rating scales or interview schedules carried out by health personnel for evaluating the degree of mental illness. Factor Construct Rating Scales (FCRS),Katz Adjustment Scales,Lorr's Inpatient Multidimensional Psychiatric Rating Scale,Wittenborn Scales,Edinburgh Postnatal Depression Scale,Mini International Neuropsychiatric Interview
D001921 Brain The part of CENTRAL NERVOUS SYSTEM that is contained within the skull (CRANIUM). Arising from the NEURAL TUBE, the embryonic brain is comprised of three major parts including PROSENCEPHALON (the forebrain); MESENCEPHALON (the midbrain); and RHOMBENCEPHALON (the hindbrain). The developed brain consists of CEREBRUM; CEREBELLUM; and other structures in the BRAIN STEM. Encephalon
D003430 Cross-Sectional Studies Studies in which the presence or absence of disease or other health-related variables are determined in each member of the study population or in a representative sample at one particular time. This contrasts with LONGITUDINAL STUDIES which are followed over a period of time. Disease Frequency Surveys,Prevalence Studies,Analysis, Cross-Sectional,Cross Sectional Analysis,Cross-Sectional Survey,Surveys, Disease Frequency,Analyses, Cross Sectional,Analyses, Cross-Sectional,Analysis, Cross Sectional,Cross Sectional Analyses,Cross Sectional Studies,Cross Sectional Survey,Cross-Sectional Analyses,Cross-Sectional Analysis,Cross-Sectional Study,Cross-Sectional Surveys,Disease Frequency Survey,Prevalence Study,Studies, Cross-Sectional,Studies, Prevalence,Study, Cross-Sectional,Study, Prevalence,Survey, Cross-Sectional,Survey, Disease Frequency,Surveys, Cross-Sectional
D005026 Ethylene Glycols An ethylene compound with two hydroxy groups (-OH) located on adjacent carbons. They are viscous and colorless liquids. Some are used as anesthetics or hypnotics. However, the class is best known for their use as a coolant or antifreeze. Dihydroxyethanes,Ethanediols,Glycols, Ethylene
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly

Related Publications

Ann Hake, and Paula T Trzepacz, and Shufang Wang, and Peng Yu, and Michael Case, and Helen Hochstetler, and Michael M Witte, and Elisabeth K Degenhardt, and Robert A Dean, and
Using florbetapir positron emission tomography to explore cerebrospinal fluid cut points and gray zones in small sample sizes.
December 2015, Alzheimer's & dementia (Amsterdam, Netherlands),
Ann Hake, and Paula T Trzepacz, and Shufang Wang, and Peng Yu, and Michael Case, and Helen Hochstetler, and Michael M Witte, and Elisabeth K Degenhardt, and Robert A Dean, and
Longitudinal pathways of cerebrospinal fluid and positron emission tomography biomarkers of amyloid-β positivity.
October 2021, Molecular psychiatry,
Ann Hake, and Paula T Trzepacz, and Shufang Wang, and Peng Yu, and Michael Case, and Helen Hochstetler, and Michael M Witte, and Elisabeth K Degenhardt, and Robert A Dean, and
Cerebrospinal fluid circulation: evaluation by single-photon and positron emission tomography.
January 1983, AJNR. American journal of neuroradiology,
Ann Hake, and Paula T Trzepacz, and Shufang Wang, and Peng Yu, and Michael Case, and Helen Hochstetler, and Michael M Witte, and Elisabeth K Degenhardt, and Robert A Dean, and
Association of weight change with cerebrospinal fluid biomarkers and amyloid positron emission tomography in preclinical Alzheimer's disease.
February 2021, Alzheimer's research & therapy,
Ann Hake, and Paula T Trzepacz, and Shufang Wang, and Peng Yu, and Michael Case, and Helen Hochstetler, and Michael M Witte, and Elisabeth K Degenhardt, and Robert A Dean, and
Comparing positron emission tomography imaging and cerebrospinal fluid measurements of β-amyloid.
December 2013, Annals of neurology,
Ann Hake, and Paula T Trzepacz, and Shufang Wang, and Peng Yu, and Michael Case, and Helen Hochstetler, and Michael M Witte, and Elisabeth K Degenhardt, and Robert A Dean, and
Assessment of amyloid deposits by (18)F-florbetapir positron emission tomography.
October 2015, European journal of nuclear medicine and molecular imaging,
Ann Hake, and Paula T Trzepacz, and Shufang Wang, and Peng Yu, and Michael Case, and Helen Hochstetler, and Michael M Witte, and Elisabeth K Degenhardt, and Robert A Dean, and
Neuropathologic heterogeneity does not impair florbetapir-positron emission tomography postmortem correlates.
January 2014, Journal of neuropathology and experimental neurology,
Ann Hake, and Paula T Trzepacz, and Shufang Wang, and Peng Yu, and Michael Case, and Helen Hochstetler, and Michael M Witte, and Elisabeth K Degenhardt, and Robert A Dean, and
Utility of the 18F-Florbetapir positron emission tomography in systemic amyloidosis.
June 2018, Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis,
Ann Hake, and Paula T Trzepacz, and Shufang Wang, and Peng Yu, and Michael Case, and Helen Hochstetler, and Michael M Witte, and Elisabeth K Degenhardt, and Robert A Dean, and
Detection of ALECT2 amyloidosis by positron emission tomography-computed tomography imaging with florbetapir.
April 2017, British journal of haematology,
Ann Hake, and Paula T Trzepacz, and Shufang Wang, and Peng Yu, and Michael Case, and Helen Hochstetler, and Michael M Witte, and Elisabeth K Degenhardt, and Robert A Dean, and
Cerebrospinal fluid and positron-emission tomography biomarkers for noradrenergic dysfunction in neurodegenerative diseases: a systematic review and meta-analysis.
January 2023, Brain communications,
Copied contents to your clipboard!